[EATG Global HIV News daily digest] Digest #187-2009

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Combination
antiretroviral therapy effective at reducing HIV resistance in mothers
and babies following mother-to-child transmission
  Prevention Wednesday 28 October 2009
					
  
Adding two other antiretroviral drugs to single dose nevirapine -- an
antiretroviral drug given to women and newborn children during labor
and delivery to prevent transmission -- is effective in reducing the
drug resistance that nevirapine causes when used by itself.
  SOURCE:
ScienceDaily




  Cochrane review of pegylated interferon plus ribavirin for hepatitis C treatment in people with HIV
  Hepatitis Wednesday 28 October 2009
					
  
Pegylated interferon plus ribavirin is an appropriate standard of care
for HIV-HCV coinfected patients, with sustained virological response
rates of 26% for hepatitis C virus genotypes 1 or 4 and 57% for
genotyes 2 or 3.
  SOURCE:
HIVandHepatitis.com




  Swedish HIVIS prime-boost vaccine shows promising results in Tanzania trial
  Prevention Wednesday 28 October 2009
					
  
An experimental vaccine combining an HIV DNA plasmid primer and a
modified vaccinia Ankara (MVA) booster induced CD4+ and CD8+ T-cell
responses in most recipients in a Phase 2 trial in Sweden, researchers
reported at the AIDS Vaccine 2009 conference last week in Paris.
  SOURCE:
HIVandHepatitis.com




  Eastern Europe and Central Asia HIV conference for joint efforts towards Universal Access
  World Policy Wednesday 28 October 2009
					
  
About 1.5 million people were estimated to be living with HIV in
Eastern Europe and Central Asia in 2007; almost 90% of them living in
either the Russian Federation or Ukraine. 
  SOURCE:
UNAIDS




  Interim
results from Study 107 highlight the potential role of telaprevir-based
regimens in HCV patients who failed prior treatment
  Hepatitis Wednesday 28 October 2009
					
  
Results provide further support for the ongoing Phase 3 registration study, REALIZE, in treatment-failure patients.
  SOURCE:
Vertex Pharmaceuticals Incorporated


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20091028/5a2a2b71/attachment.html>